Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Content validity FACIT-fatigue Psoriatic arthritis Psychometric properties Tofacitinib

Journal

Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688

Informations de publication

Date de publication:
24 Jan 2019
Historique:
received: 27 06 2018
accepted: 04 01 2019
entrez: 26 1 2019
pubmed: 27 1 2019
medline: 27 1 2019
Statut: epublish

Résumé

To evaluate the measurement properties (e.g. content validity, reliability and ability to detect change) of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale in patients with active psoriatic arthritis (PsA). One-on-one semi-structured qualitative interviews with adult patients with active PsA evaluated the content validity of FACIT-Fatigue. Quantitative measurement properties were evaluated using data from phase III tofacitinib randomized controlled trials (RCTs) in PsA: OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439). Of 12 patients included in the qualitative study, 2 (17%) had mild, 8 (67%) had moderate, and 2 (17%) had severe PsA disease activity; 7 (58%) attributed fatigue to PsA, and 7 (58%) rated fatigue as important or extremely important. Most patients considered the FACIT-Fatigue items relevant to their PsA experience and understood item content and response options as intended. In the psychometric analysis of RCT data, a second-order confirmatory factor model fit the data well (Bentler's Comparative Fit Index ≥0.92). FACIT-Fatigue demonstrated good internal consistency (Cronbach's coefficient α ≥ 0.90), test-retest reliability (Intraclass Correlation Coefficient ≥ 0.80) and a strong correlation with SF-36 Vitality (r > 0.80). A robust relationship between disease activity (based on Patient's Global Assessment of Psoriasis and Arthritis) and FACIT-Fatigue was observed (effect sizes > 1.4), with clinically important difference for the FACIT-Fatigue total score estimated as 3.1 points, and the responder definition estimated as a 4-point improvement for FACIT-Fatigue total score. Fatigue was confirmed to be an important symptom to patients with PsA, and FACIT-Fatigue was found to be a reliable and valid measure in this population.

Sections du résumé

BACKGROUND BACKGROUND
To evaluate the measurement properties (e.g. content validity, reliability and ability to detect change) of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale in patients with active psoriatic arthritis (PsA).
METHODS METHODS
One-on-one semi-structured qualitative interviews with adult patients with active PsA evaluated the content validity of FACIT-Fatigue. Quantitative measurement properties were evaluated using data from phase III tofacitinib randomized controlled trials (RCTs) in PsA: OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439).
RESULTS RESULTS
Of 12 patients included in the qualitative study, 2 (17%) had mild, 8 (67%) had moderate, and 2 (17%) had severe PsA disease activity; 7 (58%) attributed fatigue to PsA, and 7 (58%) rated fatigue as important or extremely important. Most patients considered the FACIT-Fatigue items relevant to their PsA experience and understood item content and response options as intended. In the psychometric analysis of RCT data, a second-order confirmatory factor model fit the data well (Bentler's Comparative Fit Index ≥0.92). FACIT-Fatigue demonstrated good internal consistency (Cronbach's coefficient α ≥ 0.90), test-retest reliability (Intraclass Correlation Coefficient ≥ 0.80) and a strong correlation with SF-36 Vitality (r > 0.80). A robust relationship between disease activity (based on Patient's Global Assessment of Psoriasis and Arthritis) and FACIT-Fatigue was observed (effect sizes > 1.4), with clinically important difference for the FACIT-Fatigue total score estimated as 3.1 points, and the responder definition estimated as a 4-point improvement for FACIT-Fatigue total score.
CONCLUSION CONCLUSIONS
Fatigue was confirmed to be an important symptom to patients with PsA, and FACIT-Fatigue was found to be a reliable and valid measure in this population.

Identifiants

pubmed: 30680661
doi: 10.1186/s41687-019-0094-5
pii: 10.1186/s41687-019-0094-5
pmc: PMC6346693
doi:

Banques de données

ClinicalTrials.gov
['NCT01877668', 'NCT01882439']

Types de publication

Journal Article Retracted Publication

Langues

eng

Pagination

5

Commentaires et corrections

Type : RepublishedIn
Type : RetractionIn

Références

J Rheumatol. 2001 Feb;28(2):400-5
pubmed: 11246687
J Rheumatol. 2001 Feb;28(2):406-12
pubmed: 11246688
Qual Life Res. 2000;9(8):887-900
pubmed: 11284208
J Pain Symptom Manage. 2002 Dec;24(6):547-61
pubmed: 12551804
Med Care. 2003 May;41(5):582-92
pubmed: 12719681
Qual Life Res. 1992 Feb;1(1):73-5
pubmed: 1301117
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
pubmed: 15708927
J Rheumatol. 2005 May;32(5):811-9
pubmed: 15868614
J Clin Epidemiol. 2005 Dec;58(12):1217-9
pubmed: 16291464
Health Qual Life Outcomes. 2006 Sep 27;4:70
pubmed: 17005038
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Ann Rheum Dis. 2007 Jul;66(7):936-9
pubmed: 17324972
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
J Clin Epidemiol. 2008 Jul;61(7):705-13
pubmed: 18359189
Pharmacoeconomics. 2008;26(5):363-70
pubmed: 18429654
Value Health. 2009 Nov-Dec;12(8):1075-83
pubmed: 19804437
Expert Rev Pharmacoecon Outcomes Res. 2004 Oct;4(5):581-5
pubmed: 19807551
J Clin Epidemiol. 2010 Jul;63(7):737-45
pubmed: 20494804
Support Care Cancer. 2011 Sep;19(9):1441-50
pubmed: 20706850
J Rheumatol. 2011 Jul;38(7):1355-62
pubmed: 21572156
Value Health. 2011 Dec;14(8):967-77
pubmed: 22152165
Value Health. 2011 Dec;14(8):978-88
pubmed: 22152166
Eur J Dermatol. 2012 Nov-Dec;22(6):762-9
pubmed: 23178916
Qual Life Res. 2013 Oct;22(8):1889-905
pubmed: 23288613
J Rheumatol. 2013 Jul;40(7):1158-65
pubmed: 23588944
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1085-92
pubmed: 24339179
J Orthop Sports Phys Ther. 2014 Mar;44(3):206-16
pubmed: 24450369
Ann Rheum Dis. 2014 Jun;73(6):1012-9
pubmed: 24790067
Clin Rheumatol. 2016 Feb;35(2):409-15
pubmed: 26272057
Arthritis Rheumatol. 2016 May;68(5):1060-71
pubmed: 26749174
J Clin Epidemiol. 2016 May;73:128-34
pubmed: 26939927
Joint Bone Spine. 2016 Jul;83(4):439-43
pubmed: 27055727
Ann Rheum Dis. 2017 Jan;76(1):203-207
pubmed: 27169431
Ann Rheum Dis. 2016 Apr;76(4):673-680
pubmed: 27613807
J Rheumatol. 2017 Oct;44(10):1522-1528
pubmed: 28148697
Patient Relat Outcome Meas. 2017 Jun 08;8:71-81
pubmed: 28652836
N Engl J Med. 2017 Oct 19;377(16):1525-1536
pubmed: 29045207
N Engl J Med. 2017 Oct 19;377(16):1537-1550
pubmed: 29045212
Arch Phys Med Rehabil. 2018 Sep;99(9):1827-1839.e6
pubmed: 29704507
Qual Life Res. 2018 Sep;27(9):2443-2451
pubmed: 29797175
J Pain Symptom Manage. 1997 Feb;13(2):63-74
pubmed: 9095563

Auteurs

David Cella (D)

Department of Medical Social Sciences, Northwestern University, 633 N. St. Clair Suite 1900, Chicago, IL, 60611, USA. d-cella@northwestern.edu.

Hilary Wilson (H)

Evidera, Bethesda, MD, USA.

Huda Shalhoub (H)

Evidera, Waltham, MA, USA.

Dennis A Revicki (DA)

Evidera, Bethesda, MD, USA.

Joseph C Cappelleri (JC)

Pfizer Inc, Groton, CT, USA.

Andrew G Bushmakin (AG)

Pfizer Inc, Groton, CT, USA.

Elizabeth Kudlacz (E)

Pfizer Inc, Groton, CT, USA.

Ming-Ann Hsu (MA)

Pfizer Inc, Groton, CT, USA.

Classifications MeSH